NinePointTwo Capital’s Ginkgo Bioworks DNA Stock Holding History

NinePointTwo Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,329	Closed	-$536K	–	213
2022 Q1	$536K	Buy	+3,329	New	+$648K	0.15%	37

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NinePointTwo Capital's DNA Position: Q2 2022 in Review

NinePointTwo Capital sold out of Ginkgo Bioworks (DNA) in Q2 2022, closing a stake of 3,329 shares — an estimated $536K sold.

NinePointTwo Capital first reported a position in DNA in Q1 2022 and held it in 1 quarter. The position peaked at $536K in Q1 2022. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

NinePointTwo Capital reported no remaining Ginkgo Bioworks position as of Q2 2022 after selling out during the quarter.
NinePointTwo Capital sold 3,329 Ginkgo Bioworks shares in Q2 2022, an estimated $536K.
NinePointTwo Capital first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 1 quarter.
NinePointTwo Capital's Ginkgo Bioworks position peaked at $536K in Q1 2022.
260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on NinePointTwo Capital's 13F filing for Q2 2022, filed 15 Aug 2022.